The Latvian Competition Council concludes its market study on reimbursable pharmaceuticals

Final conclusions of market study on reimbursable pharmaceuticals* On December 5, 2016 the Competition Council confirmed the final conclusions of the market study on reimbursable pharmaceuticals (hereinafter – Study) that revealed competition problems in the market, to which possible solutions were proposed. The findings of the Study show that current legal regulation in the market of reimbursable pharmaceuticals is inefficient since it restricts the entry of analogous but cheaper pharmaceuticals. Besides, legal regulation creates favorable

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Latvian Competition Authority, The Latvian Competition Council concludes its market study on reimbursable pharmaceuticals, 5 December 2016, e-Competitions Bulletin December 2016, Art. N° 82451

Visites 75

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues